secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001683168-22-003391
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals CEO Gerrit Dispersyn departs; Geert Cauwenbergh appointed interim CEO/CFO
--------------------------------------------------------------------------------

- President and CEO Gerrit Dispersyn left the company effective May 5, 2022; board reduced from eight to seven.
- Dispersyn to receive six months base salary severance plus six months medical/dental premium contributions.
- Director Geert Cauwenbergh appointed interim principal executive and financial officer effective May 5, 2022.
- Cauwenbergh previously served as Phio CEO from 2012 to 2019; will receive $7,500 monthly cash payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316822003391/0001683168-22-003391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316822003391/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-003391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer